DDInter714 DDInter1658
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pralsetinib
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Fedratinib may lead to a major life threatening interaction when taken with Tamoxifen
Fedratinib may lead to a major life threatening interaction when taken with Lurbinectedin